Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Joan S. Brugge is active.

Publication


Featured researches published by Joan S. Brugge.


Methods | 2003

Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures.

Jayanta Debnath; Senthil K. Muthuswamy; Joan S. Brugge

The three-dimensional culture of MCF-10A mammary epithelial cells on a reconstituted basement membrane results in formation of polarized, growth-arrested acini-like spheroids that recapitulate several aspects of glandular architecture in vivo. Oncogenes introduced into MCF-10A cells disrupt this morphogenetic process, and elicit distinct morphological phenotypes. Recent studies analyzing the mechanistic basis for phenotypic heterogeneity observed among different oncogenes (e.g., ErbB2, cyclin D1) have illustrated the utility of this three-dimensional culture system in modeling the biological activities of cancer genes, particularly with regard to their ability to disrupt epithelial architecture during the early aspects of carcinoma formation. Here we provide a collection of protocols to culture MCF-10A cells, to establish stable pools expressing a gene of interest via retroviral infection, as well as to grow and analyze MCF-10A cells in three-dimensional basement membrane culture.


Nature Reviews Cancer | 2005

Modelling glandular epithelial cancers in three-dimensional cultures

Jayanta Debnath; Joan S. Brugge

Little is known about how the genotypic and molecular abnormalities associated with epithelial cancers actually contribute to the histological phenotypes observed in tumours in vivo. 3D epithelial culture systems are a valuable tool for modelling cancer genes and pathways in a structurally appropriate context. Here, we review the important features of epithelial structures grown in 3D basement membrane cultures, and how such models have been used to investigate the mechanisms associated with tumour initiation and progression.


Nature Cell Biology | 2002

Sensing the environment: a historical perspective on integrin signal transduction

Cindy K. Miranti; Joan S. Brugge

Cell adhesion mediated by integrin receptors has a critical function in organizing cells in tissues and in guiding haematopoietic cells to their sites of action. However, integrin adhesion receptors have broader functions in regulating cell behaviour through their ability to transduce bi-directional signals into and out of the cell and to engage in reciprocal interactions with other cellular receptors. This historical perspective traces the key findings that have led to our current understanding of these important functions of integrins.


Cell | 2002

The Role of Apoptosis in Creating and Maintaining Luminal Space within Normal and Oncogene-Expressing Mammary Acini

Jayanta Debnath; Kenna R. Mills; Nicole L. Collins; Mauricio J. Reginato; Senthil K. Muthuswamy; Joan S. Brugge

We have utilized in vitro three-dimensional epithelial cell cultures to analyze the role of apoptosis in the formation and maintenance of a hollow glandular architecture. Lumen formation is associated with the selective apoptosis of centrally located cells; this apoptosis follows apicobasal polarization and precedes proliferative suppression during acinar development. Notably, either inhibiting apoptosis (by exogenously expressing antiapoptotic Bcl family proteins) or enhancing proliferation (via Cyclin D1 or HPV E7 overexpression) does not result in luminal filling, suggesting glandular architecture is resistant to such isolated oncogenic insults. However, the lumen is filled when oncogenes that enhance proliferation are coexpressed with those that inhibit apoptosis, or when ErbB2, which induces both activities, is activated by homodimerization. Hence, apoptosis can counteract increased proliferation to maintain luminal space, suggesting that tumor cells must restrain apoptosis to populate the lumen.


Nature | 1977

Identification of a transformation-specific antigen induced by an avian sarcoma virus

Joan S. Brugge; Raymond L. Erikson

GENETIC analyses of avian sarcoma viruses (ASV) have led to the identification of a gene, designated src, which encodes a product required for the initiation and maintenance of neoplastic transformation in infected fibroblasts1–5. Because the src gene product has not been identified biochemically, this study was initiated to detect a transformation-specific protein, using serum from rabbits bearing ASV-induced tumours. We describe here the identification of a 60,000-MW transformation-specific antigen detectable in ASV-transformed chicken cells and ASV-induced hamster tumour cells by immunoprecipitation of radiolabelled cell extracts with serum from tumour-bearing rabbits. Moreover, the expression of this antigen is temperature dependent in chicken cells transformed by an ASV temperature-sensitive mutant in the src gene. The use of this antiserum may lead to the unequivocal identification and characterisation of the ASV src gene product and this, in turn, may lead to the elucidation of the mechanism of ASV-induced oncogenesis.


Proceedings of the National Academy of Sciences of the United States of America | 2006

Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon

Michael Overholtzer; Jianmin Zhang; Gromoslaw A. Smolen; Beth Muir; Wenmei Li; Dennis C. Sgroi; Deng Cx; Joan S. Brugge; Daniel A. Haber

In a screen for gene copy-number changes in mouse mammary tumors, we identified a tumor with a small 350-kb amplicon from a region that is syntenic to a much larger locus amplified in human cancers at chromosome 11q22. The mouse amplicon contains only one known gene, Yap, encoding the mammalian ortholog of Drosophila Yorkie (Yki), a downstream effector of the Hippo(Hpo)–Salvador(Sav)–Warts(Wts) signaling cascade, recently identified in flies as a critical regulator of cellular proliferation and apoptosis. In nontransformed mammary epithelial cells, overexpression of human YAP induces epithelial-to-mesenchymal transition, suppression of apoptosis, growth factor-independent proliferation, and anchorage-independent growth in soft agar. Together, these observations point to a potential oncogenic role for YAP in 11q22-amplified human cancers, and they suggest that this highly conserved signaling pathway identified in Drosophila regulates both cellular proliferation and apoptosis in mammalian epithelial cells.


Nature Genetics | 2011

Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis

Jason W. Locasale; Alexandra R. Grassian; Tamar Melman; Costas A. Lyssiotis; Katherine R. Mattaini; Adam J. Bass; Gregory J. Heffron; Christian M. Metallo; Taru A. Muranen; Hadar Sharfi; Atsuo T. Sasaki; Dimitrios Anastasiou; Edouard Mullarky; Natalie I. Vokes; Mika Sasaki; Rameen Beroukhim; Gregory Stephanopoulos; Azra H. Ligon; Matthew Meyerson; Andrea L. Richardson; Lynda Chin; Gerhard Wagner; John M. Asara; Joan S. Brugge; Lewis C. Cantley; Matthew G. Vander Heiden

Most tumors exhibit increased glucose metabolism to lactate, however, the extent to which glucose-derived metabolic fluxes are used for alternative processes is poorly understood. Using a metabolomics approach with isotope labeling, we found that in some cancer cells a relatively large amount of glycolytic carbon is diverted into serine and glycine metabolism through phosphoglycerate dehydrogenase (PHGDH). An analysis of human cancers showed that PHGDH is recurrently amplified in a genomic region of focal copy number gain most commonly found in melanoma. Decreasing PHGDH expression impaired proliferation in amplified cell lines. Increased expression was also associated with breast cancer subtypes, and ectopic expression of PHGDH in mammary epithelial cells disrupted acinar morphogenesis and induced other phenotypic alterations that may predispose cells to transformation. Our findings show that the diversion of glycolytic flux into a specific alternate pathway can be selected during tumor development and may contribute to the pathogenesis of human cancer.


Cell | 1992

Ras is essential for nerve growth factor- and phorbol ester-induced tyrosine phosphorylation of MAP kinases

Sheila M. Thomas; Michael DeMarco; Gabriella D'Arcangelo; Simon Halegoua; Joan S. Brugge

Treatment of PC12 cells with nerve growth factor (NGF) induces a rapid increase in tyrosine phosphorylation of multiple cellular proteins. Expression of a dominant inhibitory Ras mutant specifically blocked NGF- and TPA-induced tyrosine phosphorylation of two proteins of approximately 42 and 44 kd. Conversely, expression of an oncogenic variant of Ras induced tyrosine phosphorylation of the same 42 and 44 kd proteins. The 44 kd protein was immunoprecipitated with an antibody directed against extracellular signal-regulated kinase 1/mitogen-activated protein kinase (MAPK) and the 42 kd protein comigrated with a 42 kd MAPK, indicating that at least one and probably both Ras-regulated phosphoproteins are MAPKs. In addition, MAPK activation, as measured by in vitro phosphorylation of myelin basic protein, was also regulated by Ras. Ras was not required for NGF-induced activation of Trk or tyrosine phosphorylation of PLC-gamma 1. Thus, NGF-induced tyrosine phosphorylation occurs both prior to and following Ras action, and Ras plays a critical role in the NGF- and TPA-induced tyrosine phosphorylation of MAPKs.


Cell | 2009

Mutant p53 Drives Invasion by Promoting Integrin Recycling

Patricia A. J. Muller; Patrick T. Caswell; Brendan Doyle; Marcin P. Iwanicki; Ee H. Tan; Saadia A. Karim; Natalia Lukashchuk; David A. Gillespie; Robert L. Ludwig; Pauline Gosselin; Anne Cromer; Joan S. Brugge; Owen J. Sansom; Jim C. Norman; Karen H. Vousden

p53 is a tumor suppressor protein whose function is frequently lost in cancers through missense mutations within the Tp53 gene. This results in the expression of point-mutated p53 proteins that have both lost wild-type tumor suppressor activity and show gain of functions that contribute to transformation and metastasis. Here, we show that mutant p53 expression can promote invasion, loss of directionality of migration, and metastatic behavior. These activities of p53 reflect enhanced integrin and epidermal growth factor receptor (EGFR) trafficking, which depends on Rab-coupling protein (RCP) and results in constitutive activation of EGFR/integrin signaling. We provide evidence that mutant p53 promotes cell invasion via the inhibition of TAp63, and simultaneous loss of p53 and TAp63 recapitulates the phenotype of mutant p53 in cells. These findings open the possibility that blocking alpha5/beta1-integrin and/or the EGF receptor will have therapeutic benefit in mutant p53-expressing cancers.


Nature Cell Biology | 2001

ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini

Senthil K. Muthuswamy; Dongmei Li; Sophie A. Lelièvre; Mina J. Bissell; Joan S. Brugge

Both ErbB1 and ErbB2 are overexpressed or amplified in breast tumours. To examine the effects of activating ErbB receptors in a context that mimics polarized epithelial cells in vivo, we activated ErbB1 and ErbB2 homodimers in preformed, growth-arrested mammary acini cultured in three-dimensional basement membrane gels. Activation of ErbB2, but not that of ErbB1, led to a reinitiation of cell proliferation and altered the properties of mammary acinar structures. These altered structures share several properties with early-stage tumours, including a loss of proliferative suppression, an absence of lumen, retention of the basement membrane and a lack of invasive properties. ErbB2 activation also disrupted tight junctions and the cell polarity of polarized epithelia, whereas ErbB1 activation did not have any effect. Our results indicate that ErbB receptors differ in their ability to induce early stages of mammary carcinogenesis in vitro and this three-dimensional model system can reveal biological activities of oncogenes that cannot be examined in vitro in standard transformation assays.

Collaboration


Dive into the Joan S. Brugge's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gordon B. Mills

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michael Overholtzer

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Eleanor Erikson

University of Colorado Boulder

View shared research outputs
Top Co-Authors

Avatar

Raymond L. Erikson

University of Colorado Boulder

View shared research outputs
Top Co-Authors

Avatar

Ronny Drapkin

University of Pennsylvania

View shared research outputs
Researchain Logo
Decentralizing Knowledge